CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...

The 1-year event-free survival rate was 75.5%, and the 1-year overall survival rate was 93.5%. Bicistronic CD19/CD22 chimeric antigen receptor (CAR) T-cell therapy can produce durable complete ...

SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell ...

CURE® selected some of the top stories from our coverage of the hematology conference. A phase 2 study explored a novel bicistronic CD19/CD22-directed CAR-T cell therapy for children with B-cell acute ...

Request To Download Free Sample of This Strategic Report @ The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global CAR T ...

尽管CRISPR/Cas9技术已广泛应用于基因编辑领域，实现了高效的靶向基因敲除和单碱基编辑，但大片段基因精准定点整合仍然是技术难点。当前的基因递送技术面临诸多挑战：病毒载体存在多重局限性, ...

After hours: January 13 at 4:33:49 PM EST Loading Chart for IPSC ...

horse racing stakes today FDA issues 42 warning letters regarding COVID-19 products The number of confirmed cases of COVID-19 worldwide exceeds 50 million! Understand the global epidemic in one ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...